44 results about "Fatty acid level" patented technology

The present invention relates to a method of treating a fatty acid synthesis related disease comprising administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis, wherein the fatty acid synthesis related disease is obesity, diabetes, or cardiovascular disease. The present invention also relates to a method of treating a cancer in a subject comprising: (i) identifying a level of fatty acid in a sample from the subject, and (ii) administering an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis in the subject, wherein the administration is based on the level of fatty acid, thereby treating the cancer in the subject. The present invention further relates to a method of treating Her-2 related cancers by administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis.

By this invention, novel nucleic acid sequences are provided, wherein said nucleic acid sequence is a genomic sequence of a plant desaturase encoding sequence. Also provided in the present invention are the promoter and intron sequences of the desaturase genomic sequences. Furthermore, recombinant DNA constructs employing the polynucleotide sequences are provided. The instant invention also provides methods for the modification of fatty acid compositions in host plant cells.

Methods of fortifying animal feeds nutrients typically lacking therefrom through the action of microorganisms are provided. Fermentation of animal feed materials with selected microorganisms, such as certain varieties of red yeasts, are shown to fortify the feed materials with natural carotenoids. Further, in certain embodiments, these methods can result in an increase in levels of nutritionally beneficial fatty acids, and a decrease in dietary fiber and nitrogen levels.

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

A method is described for the early detection of stroke which uses a reagent which includes a fluorescently modified fatty acid binding protein. A fluorescence difference is noted between the bound and unbound condition. Elevated levels of unbound free fatty acids from blood are used as indicators of stroke.

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

The present invention relates to a process for selectively producing sophorolactone without use of organic solvent, comprising the steps of: -pre-cultivating cells of a Candida species capable of producing sophorolactone, in absence of an oily substrate until a stationary growth phase is obtained, -cultivating said pre-cultivated cells in an aqueous medium in the presence of at least one fermentable sugar and substrate; the reaction mixture of sugar, substrate and pre-cultivated cells being present in an amount and conditions such that the cells metabolize the sugar and substrate thereby forming sophorolactone and fatty acid, -continuously feeding said substrate to said cells thereby suppressing the formation of fatty acid and keeping fatty acid levels in the reaction mixture below 10 g / l, resulting in the crystallization of at least part of the sophorolactone present in the reaction mixture, -warming the reaction mixture to a temperature between 60° C. and 90° C., thereby melting the sophorolactone crystals, -allowing the molten sophorolactone to settle and to provide a crude sophorolactone composition, and -removing the crude sophorolactone composition from the remainder of the reaction mixture without use of an organic solvent.

The present invention is directed to methods for reducing acrylamides in carbohydrate glycemic foods without the use of chelating compounds, chemicals, carbonyl group blockers, multivalent cation or other additives. The present invention further includes methods for preventing carcinogenic contaminants in cooking oil, by way of managing various factors that contribute to extreme oil degradation, as well as monitoring free fatty acid levels and polar compounds in the oil during high heat frying (e.g., lipid hydroperoxides, polymers, triglycerides, etc.) in order to ensure that the cooking oil is safe.

The invention provides methods, therapeutics and kits for treating and preventing diseases or conditions associated with excessive lipolysis, in particular TNF-α induced lipolysis, and / or excessive free fatty acid levels. Exemplary conditions include insulin-resistance, diabetes, in particular NIDDM, obesity, glucose intolerance, hyperinsulinemia, polycystic ovary syndrome, and coronary artery disease. In a preferred embodiment, the method includes administering to a subject in need a pharmaceutically effective amount of an inhibitor of the JNK signal transduction pathway and / or an inhibitor of the MAPK / ERK signal transduction pathway.

The present invention relates to a method of treating a fatty acid synthesis related disease comprising administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis, wherein the fatty acid synthesis related disease is obesity, diabetes, or cardiovascular disease. The present invention also relates to a method of treating a cancer in a subject comprising: (i) identifying a level of fatty acid in a sample from the subject, and (ii) administering an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis in the subject, wherein the administration is based on the level of fatty acid, thereby treating the cancer in the subject. The present invention further relates to a method of treating Her-2 related cancers by administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis.

A novel processing method of producing a solid fat products from air flotation sludge fat, vegetable soap stock and an oily liquid oil ingredient with more than 15% free fatty acid level on a fat basis is provided. The liquid fat or oil ingredient is heated to above 85 degree C., mixed with an alkali, dried to less than 18% moisture, and cooled to below 45 degree C. to convert the oily liquid fat or oil ingredient into the solid fat product in dry form. The product has the bypass fat function. The product is free-flowing and easy to be handled, delivered and applied.

The present invention provides method for increasing levels of epoxygenated fatty acids by administration of a phosphodiesterase inhibitor.

The invention discloses an application of andrographolide C to preparation of a weight-losing food or medicine and an application of a medicine composition composed of the andrographolide C which is used as an active component and a pharmaceutically-acceptable additive to preparation of the weight-losing food or medicine. According to the application, the technical prejudices in the prior art that andrographolide does not have the weight-losing effect are overcome and an application field of the andrographolide C is expanded. A cell experiment shows that the andrographolide C can inhibit the proliferation of 3T3-L1 preadipocytes through an oxidative stress way; the preadipocytes can be effectively prevented from being differentiated to fat cells and lipids in the fat cells are promoted to be decomposed. A mouse experiment shows that the andrographolide C has obvious effects on reducing the growth rate of body mass of a mouse, the food utilization rate and the in-vivo fat, and a dosage dependency relation is formed; the mouse blood glucose level and the serum cholesterol level can be effectively reduced, and the serum free fatty acid level and the oxidation resistance level are improved.

The present invention provides methods of increasing production of an isoprenoid or an isoprenoid precursor in a host cell, the methods generally involving modulating the level of activity of a fatty acid biosynthetic pathway enzyme in the host cell and / or culturing the host cell in a culture medium comprising a fatty acid or a compound that can be metabolized in a cell or broken down in the medium to yield a fatty acid and / or culturing the host cell in a culture medium having increased osmolarity.

The present invention provides effective Acorus calamus part extract and its medicine composition. The medicine material is Acorus calamus as one kind of Acorus Linn. plant in Araceae. The present invention has simple and reasonable extracting process for extracting effective blood sugar reducing part from Acorus calamus material. The extract has high effect, low toxicity, obvious diabetes treating activity, and may be used in medicine for treating diabetes.

The invention discloses an application of proanthocyanidins in preparing diet food or drug, and discloses an application of a drug composition with proanthocyanidins as an active component and pharmaceutically acceptable additives in preparing the diet food or drug. Mice experiments demonstrate that proanthocyanidins has obvious reduction effects for growth rate of mice body weight, food utilization rate and body fat and presents a dose-dependent relationship, can effectively reduce blood glucose level and serum cholesterol level of the mice, and can increase serum free fatty acid level and oxidation resistant level. Novel medical application and novel application field are developed for proanthocyanidins. Experiments show that the concentration of proanthocyanidins required for treating obesity is relatively low; proanthocyanidins has no side or toxic effect and has the functions of protecting human body blood circulation, enhancing immunity and protecting eyesight, thereby guaranteeing effectiveness of weight reduction and playing a promotion effect for body health.

The invention relates to a new application of a resveratrol derivative, the resveratrol derivative has effects for stabilizing mast cells, reducing obesity rat inflammatory mediator and free fatty acid levels, mitigating hyperinsulinemia and hyperleptindemia, promoting energy metabolism of adipose tissue, realizing fat-reducing effect; a molecule structural formula of the resveratrol derivative is as follows, a molecular formula of the resveratrol derivative with the above molecule structural formula is C20H22O9, the molecular weight is 406, degree of unsaturation n is 10, and a name of the is 3'-hydroxy resveratrol, 4'-O-beta-D-pyranoglucoside. the resveratrol derivative has effects for stabilizing mast cells, reducing obesity rat inflammatory mediator and free fatty acid levels, mitigating hyperinsulinemia and hyperleptindemia, promoting energy metabolism of adipose tissue, realizing fat-reducing effect; the resveratrol derivative has the advantages of obvious curative effect, no toxicity, no side effect, simple and convenient extraction, low cost and high extraction efficiency.

A neutral-fat-level-regulating agent, a cholesterol-level-regulating agent, a free-fatty-acid-level-regulating agent or an anti-obesity agent, including: at least one of protopanaxatriol, panaxatriol, protopanaxadiol and panaxadiol which are aglycons of dammarane-type saponins; and a hyperlipemia-ameliorating agent including: at least one of the neutral-fat-level-regulating agent, the cholesterol-level-regulating agent, the free-fatty-acid-level-regulating agent and the anti-obesity agent.

A novel processing method of producing a solid molasses product by a practical chemical processing method is provided. Liquid molasses is heated, mixed with calcium hydroxide at 2 to 25 percents (wt / wt) on a solid basis, dried to less than 15% moisture, and cooled to below 50 degree C. to convert the liquid molasses into the solid molasses in dry form. The solid molasses product is in block, particle or powder form. The oils with free fatty acid levels 20-80% (wt / vt) on a fat basis is added into liquid molasses and processed into molasses-fat block product with more hydrophobic function and water resistance. The process in this invention increases molasses content in the dried solid molasses from such as 42% to 90% and does not need dryer equipment, which increases the product value and reduces the related equipment and energy costs. The solid product in particle or powder form is free-flowing and easy to be handled, processed and delivered.

Methods of detecting myocardial infarction are disclosed based on elevated levels of one or more free fatty acids. The methods may comprise detection of elevated levels of total free fatty acids in a sample relative to average total free fatty acid levels in a control subject without myocardial infarction. Also disclosed are methods to detect myocardial infarction comprising detection of elevated levels of individual free fatty acids in a sample relative to those levels in a control subject and methods comprising determining whether the molar ratio of total free fatty acids to HSA is indicative of myocardial infarction.

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

The invention aims to provide a fatty acid compound applied to feed used in a laying period of a broiler chicken. The fatty acid compound comprises the following components in terms of mass percent concentration: 40-55% of fractionated palm oil, 10-15% of soybean lecithin, 40-50% of soybean oil and 3-8% of coconut oil. The fatty acid compound solid powder is used for preparing compound feed used in the laying period of the broiler chicken. The fatty acid compound solid powder has the particle size being smaller than 0.50mm, so that the digestibility of fat in a small intestine is increased. Mixed fat gives consideration to a comprehensive need of the broiler chicken on a variety of fatty acids, so that the fatty acid compound is applicable to preparation of the compound feed used in the laying period of the broiler chicken, is used for improving the fatty acid level in the compound feed for the broiler chicken, prolongs the laying period, increases the hatching rate of hatching eggs and reduces the elimination rate of chicks.

The present invention relates to animal meat enriched with [Omega]-3 polyunsaturated fatty acids for use in increasing the[Omega]-3 polyunsaturated fatty acids levels in human plasma by dietary administration of the animal meat enriched with [Omega]-3 polyunsaturated fatty acids to a subject. Also disclosed is a method of increasing the [Omega]-3 polyunsaturated fatty acids levels in human plasmacomprising dietary administration of the animal meat enriched with [Omega]-3 polyunsaturated fatty acids to the subject.